representing annual recurring revenue of $5 M. The initial five-
year supply agreement is in final stage of negotiation with
commercial quantities of resin supply commencing as soon as mid-
2008, following regulatory approval of the product.
- The Food and Drug Administration ("FDA") has granted approval to
Zymogenetics, Inc. for the commercial sale of Recothrom(R) a
recombinant thrombin product which is manufactured using a synthetic-
ligand affinity adsorbent supplied by ProMetic. This is one of ten
licenced products that have now been approved for sale by the FDA
and/or the European Medicines Agency ("EMEA") which uses ProMetic's
purification technology as part of their manufacture or function.
- Improved sensitivity by 80-fold of existing diagnostic devices was
achieved by pre-treating the samples with PRDT's enhanced concentration
technology. The results showed an added level of sensitivity to the BSE
detection process, thereby reducing the risk of "false outcomes" with
existing tests. This could allow for the detection of infectious prions
at an earlier phase in the development of the disease, thus improving
the safety of the food industry for the countries testing for BSE.
A more comprehensive update for PBI-1402 will be provided shortly as the Company is pursuing its clinical development and as partnership discussions are accelerating.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (http://www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and marketing
of a variety of commercial applications derived from its proprietary
Mimetic Ligand(TM) technology. This technology is used in large-scale
purification of biologics and the elimination of pathogens. ProMetic is
|SOURCE PROMETIC LIFE SCIENCES INC.|
Copyright©2008 PR Newswire.
All rights reserved